Cargando…

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

BACKGROUND: Efficacious vaccines are urgently needed to contain the ongoing coronavirus disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A candidate vaccine, Ad26.COV2.S, is a recombinant, replication-incompetent adenovirus serotype 26...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sadoff, Jerald, Le Gars, Mathieu, Shukarev, Georgi, Heerwegh, Dirk, Truyers, Carla, de Groot, Anne M., Stoop, Jeroen, Tete, Sarah, Van Damme, Wim, Leroux-Roels, Isabel, Berghmans, Pieter-Jan, Kimmel, Murray, Van Damme, Pierre, de Hoon, Jan, Smith, William, Stephenson, Kathryn E., De Rosa, Stephen C., Cohen, Kristen W., McElrath, M. Juliana, Cormier, Emmanuel, Scheper, Gert, Barouch, Dan H., Hendriks, Jenny, Struyf, Frank, Douoguih, Macaya, Van Hoof, Johan, Schuitemaker, Hanneke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821985/ https://www.ncbi.nlm.nih.gov/pubmed/33440088 http://dx.doi.org/10.1056/NEJMoa2034201

Ejemplares similares

LB7. Ad26.COV2.S-Elicted Neutralizing Activities Against SARS-CoV-2 Variants of Concern in Phase 1/2a and Phase 3 Clinical Trials
por: Le Gars, Mathieu, et al.
Publicado: (2021)

Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials
por: Sadoff, Jerald, et al.
Publicado: (2022)

Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine( )
por: Le Gars, Mathieu, et al.
Publicado: (2022)

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination
por: Barouch, Dan H., et al.
Publicado: (2021)

Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19
por: Barouch, Dan H., et al.
Publicado: (2021)

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
por: Hardt, Karin, et al.
Publicado: (2022)

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
por: Sadoff, Jerald, et al.
Publicado: (2022)

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
por: Sadoff, Jerald, et al.
Publicado: (2021)

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Response from the Manufacturer
por: Sadoff, Jerald, et al.
Publicado: (2021)

Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age
por: Ong-Lim, Anna Lisa, et al.
Publicado: (2022)

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
por: Alter, Galit, et al.
Publicado: (2021)

Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults
por: Leroux-Roels, Isabel, et al.
Publicado: (2020)

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
por: Bockstal, Viki, et al.
Publicado: (2022)

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment()
por: Custers, Jerome, et al.
Publicado: (2021)

A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks
por: Shukarev, Georgi, et al.
Publicado: (2016)

A plain language summary of how well the single-dose Janssen vaccine works and how safe it is
por: Sadoff, J, et al.
Publicado: (2021)

The Role of Post-Translational Modifications of Chemokines by CD26 in Cancer
por: De Zutter, Alexandra, et al.
Publicado: (2021)

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study
por: Bockstal, Viki, et al.
Publicado: (2022)

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa
por: Barry, Houreratou, et al.
Publicado: (2021)

Persistence of antibodies 20 y after vaccination with a combined hepatitis A and B vaccine
por: Van Damme, Pierre, et al.
Publicado: (2017)

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial
por: Anywaine, Zacchaeus, et al.
Publicado: (2022)

PF-4var/CXCL4L1 Predicts Outcome in Stable Coronary Artery Disease Patients with Preserved Left Ventricular Function
por: De Sutter, Johan, et al.
Publicado: (2012)

Angiostatic, tumor inflammatory and anti-tumor effects of CXCL4(47–70) and CXCL4L1(47–70) in an EGF-dependent breast cancer model
por: Van Raemdonck, Katrien, et al.
Publicado: (2014)

Quantifying Antibody Persistence After a Single Dose of COVID‐19 Vaccine Ad26.COV2.S in Humans Using a Mechanistic Modeling and Simulation Approach
por: Dari, Anna, et al.
Publicado: (2022)

Soluble cytokine receptor levels in aqueous humour of patients with specific autoimmune uveitic entities: sCD30 is a biomarker of granulomatous uveitis
por: Abu El-Asrar, Ahmed M., et al.
Publicado: (2019)

Chemokine-Induced Macrophage Polarization in Inflammatory Conditions
por: Ruytinx, Pieter, et al.
Publicado: (2018)

Serum Amyloid A1 (SAA1) Revisited: Restricted Leukocyte-Activating Properties of Homogeneous SAA1
por: Abouelasrar Salama, Sara, et al.
Publicado: (2020)

Ebola virus glycoprotein stimulates IL-18–dependent natural killer cell responses
por: Wagstaffe, Helen R., et al.
Publicado: (2020)

Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination
por: Wagstaffe, Helen R, et al.
Publicado: (2019)

Acute-serum amyloid A and A-SAA-derived peptides as formyl peptide receptor (FPR) 2 ligands
por: Abouelasrar Salama, Sara, et al.
Publicado: (2023)

Matrix Metalloproteinase-9-Generated COOH-, but Not NH(2)-Terminal Fragments of Serum Amyloid A1 Retain Potentiating Activity in Neutrophil Migration to CXCL8, With Loss of Direct Chemotactic and Cytokine-Inducing Capacity
por: Gouwy, Mieke, et al.
Publicado: (2018)

Effect of decompressive laparotomy on organ function in patients with abdominal compartment syndrome: a systematic review and meta-analysis
por: Van Damme, Lana, et al.
Publicado: (2018)

Biological Characterization of Commercial Recombinantly Expressed Immunomodulating Proteins Contaminated with Bacterial Products in the Year 2020: The SAA3 Case
por: Abouelasrar Salama, Sara, et al.
Publicado: (2020)

Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults
por: Lazarus, Rajeka, et al.
Publicado: (2016)

Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4
por: Schols, Dominique, et al.
Publicado: (1997)

Accessing Maternal Health Services in Eastern Burma
por: Douoguih, Macaya
Publicado: (2008)

Persistence of HBsAg‐specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults
por: Van Damme, Pierre, et al.
Publicado: (2019)

Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen
por: Bockstal, Viki, et al.
Publicado: (2021)

Inhibition of renal fibrosis with a human CXCL9‐derived glycosaminoglycan‐binding peptide
por: Poosti, Fariba, et al.
Publicado: (2022)

Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host  Insults
por: De Buck, Mieke, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_05vbrleg6usirk4cc7smkn1k22